CALT - calliditas.se Debt to Book Capitalization Ratio

Calliditas Therapeutics (CALT) maintains its position in the rare kidney pathology niche through its drug Tarpeyo and various support programs. The debt-to-capitalization trend confirms a stable structure, where 9.01 reflects the baseline level of the metric. High barriers to entry are ensured by patents and R&D expenditures, while the reliance on a single product is mitigated by integration into a global holding.

CALT (Calliditas Therapeutics AB) Debt to Book Value history from 07/04/2022 to 09/28/2024

calliditas.se (CALT) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Calliditas Therapeutics AB|CALT - Analyst Consensus Forecast

- market capitalization data:

Market Value Calliditas Therapeutics AB|CALT - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Calliditas Therapeutics|CALT - Company Net Assets|Market Capitalization to Book Value Ratio calliditas.se|CALT - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Calliditas Therapeutics|CALT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Calliditas Therapeutics AB|CALT - Company Aggregate Debts|Debts to Book Capitalization Calliditas Therapeutics AB

Fundamental company analysis:Calliditas

Core merchandise of Calliditas Therapeutics AB

This ratio reflects the share of total borrowings within the company's equity structure. By analyzing the dynamics of debt obligations relative to balance sheet capital, an investor determines the business's degree of financial autonomy. The metric's value depends directly on quarterly reporting data regarding debt and reserves. For Calliditas Therapeutics (CALT), low leverage is critically important, as it ensures the financial stability required to maintain costly specialized logistics for drug transportation.

Competitors of Calliditas Therapeutics